{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:10:23Z","timestamp":1778476223645,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.lungcan.2025.108633","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T01:57:08Z","timestamp":1750643828000},"page":"108633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study"],"prefix":"10.1016","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7641-9065","authenticated-orcid":false,"given":"Yoshitaka","family":"Zenke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9480-5923","authenticated-orcid":false,"given":"Seiji","family":"Niho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5983-3531","authenticated-orcid":false,"given":"Yukihiro","family":"Toi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2427-3690","authenticated-orcid":false,"given":"Yuki","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3849-5905","authenticated-orcid":false,"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0816-5315","authenticated-orcid":false,"given":"Kimio","family":"Yonesaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5856-5512","authenticated-orcid":false,"given":"Hiroaki","family":"Akamatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-9435","authenticated-orcid":false,"given":"Junko","family":"Tanizaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8791-7405","authenticated-orcid":false,"given":"Kiyonobu","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5026-8078","authenticated-orcid":false,"given":"Hiroshi","family":"Gyotoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8339-2895","authenticated-orcid":false,"given":"Toshihiro","family":"Misumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1284-9776","authenticated-orcid":false,"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7342-0853","authenticated-orcid":false,"given":"Nobuyuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.lungcan.2025.108633_b0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108633_b0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10027","key":"10.1016\/j.lungcan.2025.108633_b0015","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"10066","key":"10.1016\/j.lungcan.2025.108633_b0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108633_b0025","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"9944","key":"10.1016\/j.lungcan.2025.108633_b0030","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(14)60845-X","article-title":"Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial","volume":"384","author":"Garon","year":"2014","journal-title":"Lancet (London, England)"},{"issue":"14","key":"10.1016\/j.lungcan.2025.108633_b0035","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108633_b0040","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1200\/JCO.22.01503","article-title":"Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227","volume":"41","author":"Brahmer","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108633_b0045","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108633_b0050","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jtho.2020.09.022","article-title":"Atezolizumab Versus Docetaxel in Pretreated Patients With NSCLC: Final Results From the Randomized Phase 2 POPLAR and Phase 3 OAK Clinical Trials","volume":"16","author":"Mazieres","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108633_b0055","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejca.2023.01.025","article-title":"Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study)","volume":"184","author":"Nakamura","year":"2023","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2025.108633_b0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2020.04.021","article-title":"Addition of ramucirumab enhances docetaxel efficacy in patients who had received anti-PD-1\/PD-L1 treatment","volume":"144","author":"Tozuka","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108633_b0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000350","article-title":"Propensity score\u2013weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non\u2013small cell lung cancer (WJOG10217L)","volume":"8","author":"Kato","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.lungcan.2025.108633_b0070","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.lungcan.2016.07.019","article-title":"A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy","volume":"99","author":"Yoh","year":"2016","journal-title":"Lung Cancer (Amsterdam, Netherlands)"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005252?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225005252?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:30:16Z","timestamp":1778473816000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225005252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":14,"alternative-id":["S0169500225005252"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108633","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108633"}}